The new director of the National Institutes of Health is prioritizing making NIH-funded clinical research more inclusive and accessible to the public. The White House is supporting the use of 'march-in' rights to undermine patent rights for high-priced medicines, causing uncertainty among drugmakers. President Biden has intervened in the debate over NIH's legal authority to override exclusive patent licenses for treatments developed with agency-funded research. The administration aims to stop drug companies from using taxpayer money to develop drugs and sell them at high prices. The controversy surrounding 'march-in' rights has deep roots in California, with consumer advocates advocating for lower drug costs by seizing control of key patents. Concerns have been raised about the potential impact on bio innovation, investment leadership, and long-term investing due to weakened patent protection, price controls, and uncertain regulatory measures.
USA could lose its bio innovation advantage and investment leadership—If we 1) weaken patent protection. 2) penalize innovators w price controls/march-in rights. 3) create uncertain and random-FDA, FTC. 4) capital gains proposals that disincentivize long-term investing. Hmmmmm.
Controversial federal outline for 'march-in' rights on drugs has deep roots in California. It turns out that consumer advocates have long pushed for lower drug costs by opting to seize control of key patents. https://t.co/zSxlZ4dZcr
Controversial federal outline for 'march-in' rights on drugs has deep roots in California. It turns out that consumer advocates have long pushed for lower drug costs by opting to seize control of key patents. https://t.co/CNAvAFh53Y
Drug companies use tax-payer money to develop drugs and sell them at high prices. The White House says it must stop https://t.co/3lxuyOLl76
President Biden has stepped into a long-running debate about whether NIH has legal authority to override an exclusive patent license granted to drug developers if they charge too much for treatments that relied on agency-funded research. https://t.co/O2za2Ig6bc
The Biden administration's assertion of its authority to exercise "march-in" rights is causing uncertainty over the extent to which drugmakers may lose monopolies and consumers will save money. https://t.co/jR1XtqjvJN
The White House is throwing its support behind a controversial authority that allows the government to undermine patent rights for certain high-priced medicines. https://t.co/EocDAOOlSy
The new director of the National Institutes of Health says her highest priority is making NIH-funded clinical research more inclusive and more accessible to the public. https://t.co/dHacnDiCOj